dociparstat sodium (CX-01) / Cantex Pharma, Chimerix  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
NCT00457951: A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

Terminated
2
158
Europe, Canada, US
Open-Label, PGX-100, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, 0.9% Sodium Chloride Solution Placebo-Control Arm, ODSH
Chimerix
Chronic Obstructive Pulmonary Disease
08/09
10/09
NCT01461915: Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

Terminated
2
60
US
Nab paclitaxel, Abraxane, Gemcitabine, Dociparstat, ODSH, 2-O, 3-O Desulfated Heparin, Dociparstat sodium
Chimerix, Translational Drug Development
Metastatic Pancreatic Cancer
12/12
06/15
NCT02873338: Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Completed
2
75
US
Dociparstat sodium, 2-O, 3-O desulfated heparin, ODSH, PGX-100, CX-01, Dociparstat, Idarubicin, Idamycin, Cytarabine
Chimerix
Acute Myeloid Leukemia
06/19
06/19

Download Options